Inhibikase Therapeutics (NASDAQ:IKT) Stock Rating Upgraded by Wall Street Zen

Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Inhibikase Therapeutics Stock Performance

NASDAQ:IKT opened at $1.64 on Friday. Inhibikase Therapeutics has a 12-month low of $1.12 and a 12-month high of $4.20.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.